Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138591 | Leukemia Research | 2009 | 9 Pages |
Abstract
We have compared the cytotoxic activity of rituximab with that of blinatumomab (MT103/MEDI-538), a single-chain CD19-/CD3-bispecific antibody engaging human T cells. Blinatumomab consistently led to a higher degree of lysis of human lymphoma lines than rituximab, and was active at much lower concentration. The cytotoxicity mediated by blinatumomab and rituximab both caused a potent activation of pro-caspases 3 and 7 in target cells, a key event in induction of granzyme-mediated apoptotic cell death. Combination of rituximab with blinatumomab was found to greatly enhance the activity of rituximab, in particular at low effector-to-target cell ratios and at low antibody concentration.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sandrine d’Argouges, Sandra Wissing, Christian Brandl, Nadja Prang, Ralf Lutterbuese, Alex Kozhich, JoAnn Suzich, Mathias Locher, Peter Kiener, Peter Kufer, Robert Hofmeister, Patrick A. Baeuerle, Ralf C. Bargou,